CD24+/CD38- as new prognostic marker for non-small cell lung cancer, Multidisciplinary Respiratory Medicine
By A Mystery Man Writer
Description
Background Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result, there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer. Methods In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel. Results We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8 of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also positive for CD133 and EpCAM. Conclusions We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early detection of NSCLC.
Frontiers Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Current Oncology, Free Full-Text
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients
Precision treatment for metastatic non–small cell lung cancer: A conceptual overview
Non-Small Cell Lung Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer, Biomarker Research
Frontiers Role of CD38 in anti-tumor immunity of small cell lung cancer
Non Small Cell Lung Cancer - an overview
from
per adult (price varies by group size)